News
BioInvent receives Investigational New Drug approval for monoclonal antibody BI-1910
Swedish clinical stage biotech company BioInvent has announced that it has received Investigational New Drug (IND) approval for its monoclonal antibody, making it the second of its anti-tumour necrosis factor receptor 2 (TNFR2) programmes to enter clinical development.